Clinical trials: Pulmonary Disorder
COPD
Prospective Dynamic Cohort Study of Phenotypic Profiles in Patients With Chronic Obstructive Pulmonary Disease
This prospective, multicenter, real-world observational cohort study will describe phenotypic profiles, patient characteristics, and treatments in adults with stable chronic obstructive pulmonary disease (COPD).
- Trial name
- COPD-BPCO 2 (NCT07627763)
- Testing
- Routine care / no study-specific intervention
- Where
- 7 sites in France
- Volunteers
- 500 people
- Sponsor
- Initiatives Bronchopneumopathie Chronique Obstructive (BPCO)
Lung Neoplasm Malignant
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
Neoadjuvant chemotherapy followed by surgery has been recommended as the standard treatment for locally advanced and resectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved.
- Trial name
- NCT04973293
- Testing
- sintilimab, bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
SARS-COV2 Infection
COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey
Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.
- Trial name
- NCT04470648
- Testing
- blood test for SARS-COV2 serology
- Where
- 3 sites in France
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Bronchiolitis
Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants
Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV).
- Trial name
- BRONCHOBIOTE (NCT06161285)
- Testing
- Sampling
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lung Injury, Acute Respiratory Distress Syndrome
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
The purpose of this study was to assess the safety, tolerability and preliminary efficacy of FP-1201 (Interferon Beta) in patients with Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- NCT00789685
- Testing
- Interferon Beta
- Where
- 8 sites in United Kingdom
- Volunteers
- 37 people
- Sponsor
- Faron Pharmaceuticals Ltd
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Non-Small Cell Lung Cancer
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
The purpose of this phase II study is to find out what effects cabozantinib (XL184) has, good and/or bad, in patients whose tumors one of the following gene changes RET, ROS1, or NTRK fusion, or increased MET or AXL activity.
- Trial name
- NCT01639508
- Testing
- Cabozantinib
- Where
- 7 sites in United States
- Volunteers
- 86 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Asthma
A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists
This is a first in human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8630 in healthy adults (Part A) and adult asthma patients on medium to high dose inhaled…
- Trial name
- NCT05110976
- Testing
- AZD8630
- Where
- 29 sites in United States, Germany and 1 more
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Advanced Solid Tumors
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head…
- Trial name
- NCT01946789
- Testing
- ALT-803
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Pulmonary Disease, Chronic Obstructive, Smoking
Electronic Proactive Outreach for Smokers With COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases, with 90% of cases directly attributable to smoking. Unfortunately, many patients continue to smoke and have an urgent need to quit.
- Trial name
- NCT04462289
- Testing
- Proactive Outreach
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- VA Office of Research and Development
SARS-CoV-2 Infection
To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects
This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.
- Trial name
- NCT05017168
- Testing
- CT-P63
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celltrion
Pneumonia, Diagnosis
Metagenomic NGS for Diagnosis of Pneumonia
In this randomized controlled trial, we aim to evaluate the efficacy of incorporating mNGS in the management of pneumonia on efficiency and accuracy of causative pathogen identification, proportion of participants with effective…
- Trial name
- NCT05979350
- Testing
- Metagenomic next-generation sequencing, Standard work-up for pneumonia
- Where
- Taiwan
- Volunteers
- 114 people
- Sponsor
- National Taiwan University Hospital
Covid19
USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19
Estimation of the prevalence and contagiousness of undocumented novel coronavirus infections is critical for understanding the overall prevalence and pandemic potential of this disease.
- Trial name
- IVERCAR (NCT04425850)
- Testing
- Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops)
- Where
- Argentina
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Eurnekian Public Hospital
Adult Respiratory Distress Syndrome
PaO2/FiO2*PEEP (P/FP) Ratio and Mortality in Acute Respiratory Distress Syndrome.
The PaO2/FiO2 (P/F) ratio is same for all the Positive End Expiratory Pressure (PEEP) ≥ to 5. This P/F ratio misleads the severity of disease without the knowledge of set PEEP.
- Trial name
- NCT03946150
- Testing
- P/FP Ratio
- Where
- Singapore
- Volunteers
- 4,361 people
- Sponsor
- National University Health System, Singapore
NSCLC Stage IV, Limited Metastatic Disease
Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)
This will be a phase II trial testing if the combination of SBRT and L19-IL2 improves the progression free survival in patients with limited metastatic non-small cell lung cancer (NSCLC).
- Trial name
- ImmunoSABR (NCT02735850)
- Testing
- L19-IL2, SBRT, No intervention
- Where
- Netherlands
- Sponsor
- Maastricht Radiation Oncology
Lung Cancer
Telephone Support Program for Lung Cancer Patients and Their Family Caregivers
The goal of this project is to examine the physical and psychological health benefits of a novel, telephone-delivered symptom management intervention for advanced lung cancer patients and their family caregivers.
- Trial name
- NCT01993550
- Testing
- Telephone counseling, Education
- Where
- 3 sites in United States
- Volunteers
- 262 people
- Sponsor
- Indiana University
Pulmonary Disease, Chronic Obstructive
Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects
GSK2269557 is being developed as an anti-inflammatory and anti-infective agent for the treatment of inflammatory airways diseases.
- Trial name
- NCT03189589
- Testing
- GSK2269557 500 µg, GSK2269557 750 µg
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI
This is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung…
- Trial name
- NCT03924050
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Protein; Disease
Pilot Study on Proteomics of Erythrocyte Proteins in Patients With COPD Based on TMT Technology
Chronic obstructive pulmonary disease (COPD), a common and complex disease characterized by persistent airflow limitation, is a leading cause of mortality worldwide. COPD and its comorbidity are associated with hypoxia condition.
- Trial name
- NCT05376618
- Testing
- no intervention
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche